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Background: Researches have shown that soluble epoxide hydrolase inhibitors (sEHi) can protect against the
development of atherosclerosis. Simultaneously, emerging evidences have implicated the association between fatty
acid synthase (FAS) and acute coronary syndrome (ACS). We tested the hypothesis that sEHi could reduce the
occurrence of ACS by regulating FAS.
Methods: Hospitalized ACS patients were selected as the ACS group (n = 65) while healthy normal subjects as the
control group (n = 65). The blood levels of lipoproteins, fasting glucose, myocardial enzyme and high-sensitivity
C-reactive protein (hs-CRP) were measured within 24 hours after admission. The peripheral blood mononuclear cells
(PBMCs) were isolated and cultured. Trans-4-[4-(3-Adamantan-1-ylureido)cyclohexyloxy] benzoic acid (t-AUCB), a
kind of sEHi, was then added to cells in various concentrations (0, 10, 50, 100 μmol/L). The expression of FAS,
interleukin-6 (IL-6) mRNA and protein was detected by real-time PCR or Western blot, respectively.
Results: (1) Compared with the control group, the serum concentration of hs-CRP in the ACS group was increased
(P<0.05). The expression of FAS, IL-6 mRNA and protein were significantly increased in PBMCs from the ACS group
(all P<0.05). Moreover, the levels of FAS and IL-6 mRNA were positively correlated with the serum concentration of
hs-CRP (r = 0.685, P<0.01; r = 0.715, P<0.01) respectively. (2) The expression of FAS, IL-6 mRNA and protein in PBMCs
from the ACS group were dose-dependently inhibited by sEHi (all P<0.05).
Conclusions: sEH inhibition regulated FAS and inhibited inflammation in cultured PBMCs from ACS patients, a
mechanism that might prevent rupture of atherosclerotic lesions and protect against development of ACS.
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Acute coronary syndrome (ACS) is the leading cause of
death and loss of life worldwide. ACS usually occurs when
plaques are suddenly ruptured [1-4]. Numerous studies
have shown that the concentrations of saturated fatty acid
(SFA) in plaques and the thickness of the fibrous cap are
associated with the formation of disrupted plaques [5].
Greater concentrations of SFA (3.5 versus 2.9, P < 0.05)
have been found at the edges of disrupted plaques than* Correspondence: xudanyan02@sina.com
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reproduction in any medium, provided the orthe center, which could reflect that increased SFA levels
adversely influenced plaque stability [6,7]. Moreover,
Felton et al. [7] stated that increased SFA levels at the
edges of advanced plaques was inversely associated with
cap thickness, and therefore might reflect a predisposition
to plaque rupture. The synthesis of SFA is an energy-
consuming process that requires the multifunctional en-
zyme, fatty-acid synthase (FAS) [8]. It has been suggested
that FAS plays an important role in the development of
ACS by regulating the synthesis of SFA.
Evidence suggests that FAS is the key enzyme that regu-
lates differentiation of the monocyte into the macrophage,
and the inhibition of FAS limits phagocytosis bytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to ingest oxidized low-density lipoprotein cholesterol
(ox-LDL-C) through phagocytosis in the subendocardium,
which is the basis of the development of atherosclerosis.
Moreover, macrophages release lytic enzymes that degrade
the fibrous cap, resulting in plaque instability and rupture
[10]. Therefore, the inhibition of FAS could decrease ACS
by reducing the number of macrophages present in the
plaque and preventing phagocytosis by macrophages.
Furthermore, inflammation also plays a key role in devel-
opment of ACS [11,12]. Consequently, it is not surprising
that biomarkers of inflammation, such as high-sensitive
C-reactive protein (hs-CRP) and interleukin-6 (IL-6), have
been used to indicate inflammatory status in these dis-
eases. Likewise, the concentration of FAS was positively
correlated with the levels of inflammatory factors in vivo
[13,14]. One study showed that inflammation upregulated
FAS expression at the levels of both mRNA and protein,
and stimulated lipogenesis in non-adipose tissues, which
caused ectopic lipid deposition [15]. Taken together, these
data suggest that FAS is associated with plaque rupture
mediated by regulating lipid metabolism and inflammatory
processes.
Soluble epoxide hydrolase (sEH) is an emerging target for
pharmacological treatment of cardiovascular diseases be-
cause the inhibition of sEH leads to increased circulating
levels of epoxyeicosatrienoic acids (EETs) and other fatty
acid epoxides, which mediate endothelium-dependent vaso-
dilation, promote angiogenesis and have anti-inflammatory
properties [16-19]. sEH inhibitors (sEHi) were originally
developed as antihypertensive and anti-inflammatory
agents [20-23]. Moreover, Ulu et al. [24] found that sEHi
could reduce atherosclerotic plaque formation in the apoE-
KO mouse model. However, no studies exist regarding sEHi
for the treatment of ACS.
Based on the evidence given above, we expected that
sEHi might affect the development of ACS via stabilization
of the plaque and anti-inflammation by regulating FAS. In
our study, we showed that (1) The expression levels of FAS,
IL-6 mRNA and protein in the ACS group were obviously
increased. (2) The expression of FAS mRNA and protein in
peripheral blood mononuclear cells (PBMCs) from the
ACS group were dose-dependently inhibited by sEHi.




According to diagnosis and classifications standard of
ACS by the WHO [25], 65 patients with acute coronary
syndrome from 49.8 to 75.2 years old (64.8 ± 12.1 years),
including 38 men and 27 women, were admitted to the
ACS group. The control group comprised 65 healthy
volunteers from 53.4 to 73.2 years old (65.2 ± 10.2years), including 39 men and 26 women. Subjects were
excluded from the study if they had severe liver and kid-
ney diseases, lung diseases, fracture, carcinoma, any kind
of infectious disease, autoimmunity disease or combined
acute complications. All patients provided written
informed consent and the study was approved by the
Ethics Committee of Second Xiangya Hospital, Central
South University, Changsha, Hunan Province, China.
Methods
Biochemical analysis
All the subjects selected were admitted to hospital within
24 hours, and blood was taken for isolation and culturing
of PBMCs. Routine blood, serum concentrations of glucose,
hs-CRP, total cholesterol (TC), triglycerides (TG), LDL-C
and high density lipoprotein cholesterol (HDL-C) were
measured the following morning after fasting for 10 hours.
The methods for measurement of biochemical variables, in-
cluding fasting glucose concentrations, fasting lipoprotein
profiles and hs-CRP were described in previous study [26].
PBMCs isolation and cell culture
PBMCs were isolated from the peripheral blood by ficoll
density gradient centrifugation. PBMCs (1×106 of the
target cells per well) were cultured in complete RPMI
1640 containing 10% fetal bovine serum (FBS). The cells
were demonstrated to have >95% viability with 2% Try-
pan blue exclusion. trans-4-[4-(3-Adamantan-1-ylur-
eido)cyclohexyloxy] benzoic acid (t-AUCB) [27], a kind
of sEHi, was synthesized in the laboratory of Dr. Bruce
Hammock (UC Davis). At first, we prepared a 0.2M
stock solution by mixing 500μL of dimethylsulphoxide
(DMSO) with 41.25 mg of t-AUCB. Then, stock solution
was diluted with medium to different concentrations (0,
10, 50, 100 μmol/L) as required and used to treat cells
for 24 h. While the PBMCs from the healthy subjects
were cultured as the control without any intervention.
Real-time PCR
The cells were collected and total RNA was extracted
from cells using TRIZOL kits as recommended by the
manufacturer (Invitrogen). A total of 1 μg of total RNA
isolated from each group using an RNeasyW kit (Qiagen)
with the addition of DNase was reverse transcribed into
cDNA and then 1 μl cDNA was used to perform real-
time polymerase chain reaction assay (PCR). The primer
sequences were as follows:
FAS: F: 50CGCGTGGCCGGCTACTCCTAC30, R:
50CGGCTGCCACACGCTCCTCT30
IL-6: F: 50CAATCTGGATTCAATGAGGAGAC30, R:
50CTCTGGCTTGTTCCTCACTACTC30
GAPDH: F: 50GGAAGGTGAAGGTCGGAGTCA30, R:
50GCTCCTGGAAGATGGTGATGG30
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PCR system using SYBRW GREEN PCR Master Mix
(Applied Biosystems) as detailed in the manufacturer’s
guidelines. Cycling parameters were 95°C for 10 sec,
then 40 cycles of 95°C for 5 sec and 60°C for 31 sec. All
the effective data were statistically analysed by the 2-ΔΔCt
method.
Western blotting
The cells were collected and total protein was extracted
from cells using the kits as recommended by the manu-
facturer. Protein concentration was determined by the
bicinchonininc acid (BCA) method, and samples were
then loaded per well for sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE). The proteins
were electrophoretically transferred to polyvinylidene fluor-
ide (PVDF) membranes. The membranes were blocked
with blocking buffer, and incubated with primary anti-
bodies, followed by incubation with secondary antibodies.
At last, the bands were scanned by the GEL imaging sys-
tem, and then the bands were analyzed using Photoshop
software. All the bands were compared to β-actin as the in-
ternal control.
Statistical methods
All the data were analysed statistically using SPSS 16.0 soft-
ware package. All results were expressed as the mean ±
standard error (SE), except that hs-CRP results were loga-
rithmically transformed to approximate a normal distribu-
tion. Single comparisons were examined with Student’s
t-tests. One-way analysis of variance (ANOVA) was used
to compare several groups. A linear relationship was
assessed by least-square regression analysis. A two-sided P
value of <0.05 was considered to be statistically significant.
Results
Basic clinical characteristics of the study subjects
There was no statistical significance between the ACS
group and the control group in terms of gender, age,
number of people who smoke, body mass index (BMI),
blood pressure, fasting blood sugar (FBS), hemoglobin
(Hb), serum creatinine(Cr), TG, TC, HDL-C, LDL-C (all
P > 0.05). However, the total white blood cell count
(WBC), troponin T (cTnT), creatine kinase (CK), creat-
ine kinase isoenzyme (CK-Mb) and hs-CRP of the ACS
group were higher than the control group (P < 0.05)
(Table 1).
Expressions of FAS, IL-6 mRNA and protein in PBMCs and
their relationships with hs-CRP
As shown in Figure 1, compared with the control group,
the mRNA and protein expression levels of FAS and IL-
6 were significantly increased in the ACS group (all P <
0.05). Moreover, the levels of FAS and IL-6 mRNA werepositively correlated with the serum concentration of hs-
CRP in the ACS group (r = 0.685 P < 0.05 and r = 0.715
P < 0.05), respectively (Figure 2 and 3).
Effects of sEHi on FAS and IL-6 mRNA in PBMCs
t-AUCB had a dose-dependent inhibitory effect on the
expression of FAS, IL-6 mRNA in PBMCs from the ACS
group, and reached the maximum effect when the con-
centration of t-AUCB was 100 μmol/L. Compared with
the control group (t-AUCB: 0 μmol/L), 10, 50, 100
μmol/L levels of t-AUCB had inhibited the expression of
FAS, IL-6 mRNA in PBMCs from the ACS group with a
statistical difference (P < 0.05) (Figure 4a).
Effects of sEHi on FAS and IL-6 protein levels in PBMCs
t-AUCB had a dose-dependent inhibitory effect on the
expression of FAS, IL-6 protein in PBMCs from the ACS
group. Compared with the control group (t-AUCB: 0
μmol/L), levels of 10, 50, 100 μmol/L t-AUCB had inhib-
ited the expression of FAS, IL-6 protein in PBMCs from
the ACS group (P < 0.05). The relative expression levels
of FAS protein in the t-AUCB 0, 10, 50 and 100 μmol/L
groups were 0.957 ± 0.080, 0.935 ± 0.075, 0.855 ± 0.053,
0.685 ± 0.046, respectively. The relative expression of
IL-6 protein in the t-AUCB 0, 10, 50 and 100 μmol/L
groups were 1.276 ± 0.060, 0.9310 ± 0.064, 0.738 ± 0.044
and 0.506 ± 0.072, respectively (Figure 4b).
Discussion
Numerous studies have demonstrated that the inflamma-
tory level is increased in the ACS patients [11,12,28,29].
Shantsila and Lip [30] highlighted that monocytes were
actively involved in the pathological processes related to
ACS, which promoted the synthesis of pro-inflammatory
molecules, such as IL-6, tumor necrosis factor-α (TNF-α)
and hs-CRP. Among them, hs-CRP has been proved to
be the strongest and most significant predictor of the in-
flammatory level and the risk of plaque instability and
rupture [31-33]. Our studies showed that the serum con-
centration of hs-CRP and the total white blood cells were
elevated in the ACS group, which was in accordance with
previously published studies [34,35], indicated that in-
flammation was correlated with the development of car-
diovascular events.
Among the inflammatory factors, IL-6 induces the
production and secretion of CRP [36]. In the present
study, we found that the expressions of IL-6 mRNA and
protein in PBMCs were significantly increased in ACS
group and then levels of IL-6 mRNA were positively cor-
related with the serum concentration of hs-CRP, which
indicated that PBMCs were actived in the ACS group
and more inflammatory factors were synthesized in cells.
The disruption of unstable coronary artery plaques is
responsible for the majority of incidents of ACS [1-3,37].
Table 1 Basic clinical characteristics of the study subjects (―x  SE)
Control (n = 65) ACS (n = 65) P-Value
Gender, male/female 39/26 38/27 0.542
Smoker, (n) (% of the total) 28 (43.1) 31 (47.7) 0.493
Age (years) 65.2 ± 10.2 64.8 ± 12.1 0.419
Systolic blood pressure (mmHg) 120.7 ± 14.2 123.4 ± 14.1 0.208
Diastolic blood pressure (mmHg) 74.6 ± 10.2 70.8 ± 7.4 0.285
TG (mmol/L) 1.8 ± 1.0 1.5 ± 1.0 0.390
TC (mmol/L) 4.4 ± 0.6 4.0 ± 0.8 0.154
HDL-C (mmol/L) 1.0 ± 0.3 0.9 ± 0.3 0.067
LDL-C (mmol/L) 2.6 ± 0.7 2.4 ± 0.8 0.265
Cr (μmol/L) 74.9 ± 17.0 82.7 ± 14.8 0.489
CK (U/L) 169.2 ± 21.1 207.3 ± 30.3a 0.038
CK-Mb (U/L) 13.5 ± 5.6 38.6 ± 43.0a 0.001
cTnT (ng/mL) 4.7 ± 4.5 795.7 ± 287.1a 0.000
FBS (mmol/L) 5.1 ± 0.9 5.3 ± 1.4 0.101
WBC (×109/L) 6.9 ± 1.1 7.5 ± 2.4a 0.028
Hb (g/L) 123.0 ± 9.0 118.0 ± 13.0 0.347
BMI (Kg/m2) 22.8 ± 2.4 23.9 ± 3.0 0.086
h-CRP (mg/L) 1.3 ± 0.9 5.6 ± 4.1a 0.001
Medication history, n (%)
ACEI/ARB NE 15 (23.0) -
β- blocker NE 24 (36.9) -
Statin NE 30 (46.2) -
CCB NE 32 (49.2) -
Insulin NE 2 (3.0) -
Hospitalized ACS patients were selected as the ACS group (n = 65) while the healthy normal subjects as the control group (n = 65). The levels of routine blood
analyses, lipoproteins, fasting blood glucose, myocardial enzyme and high-sensitive C-reactive protein (hs-CRP) were determined within 24 hours after admission.
Values are mean ± SE or percentage (n) (%). a P<0.05, compared with control group.
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sclerotic plaques. Firstly, increased SFA concentrations,
which is inversely associated with cap thickness, might
reflect a predisposition to rupture [7]. Results also
showed that increased FAS in PBMCs promote synthesis
of SFA [8]. Secondly, as already noted, the disrupted
plaques are intimately related to the accumulation of
lipid-filled macrophages at their edges. Macrophage cells
produce cytokines that activate neighboring smooth
muscle cells, resulting in extracellular matrix formation,
fibrosis, and plaque instability, which play key roles in
ACS [5,38,39]. FAS is also the key enzyme of the matur-
ation of macrophages, as the uptake of modified lipopro-
teins is inhibited when fatty synthesis is suppressed
during the differentiation process of the monocyte [9].
Therefore, FAS increase the occurence of ACS by regu-
lating the synthesis of SFA and augmenting numbers of
mature macrophages in the lipid core. Our results
showed that, compared with the control group, the
expression levels of FAS mRNA were significantlyincreased in the ACS group, which provided important
evidence for the association between FAS and ACS.
A study showed that inflammation upregulated mRNA
and protein expression of FAS, and stimulated lipogen-
esis in non-adipose tissues, causing ectopic lipid depos-
ition [10]. We hypothesized that the composition of SFA
in plaques was further increased as a result of upregu-
lated FAS expression in the inflammatory state. Our
studies proved that compared with the control group,
the expression levels of FAS mRNA were positively cor-
related with the serum concentration of hs-CRP, which
showed that the variation of fatty acid metabolism
reflected high levels of inflammatory status in vivo.
Therefore, it could be speculated that the expression of
FAS in PBMCs was closely correlated with the vulner-
able state of plaques and the inflammatory levels in the
ACS patients.
Furthermore, our study also showed that the increased
expression of FAS mRNA and protein in PBMCs from
the ACS group were dose-dependently inhibited by
Figure 2 Linear relationships between expression levels of FAS
mRNA and the serum concentration of hs-CRP in ACS. PBMCs
were isolated from peripheral blood of ACS patients. FAS mRNA was
detected by realtime-PCR. Hs-CRP was measured by immune
nephelometry. Relative expression levels of FAS mRNA means its
2-ΔΔCt value. Hs-CRP was log transformed to achieve normal
distribution. The linear relationship between expression levels of FAS
mRNA and serum concentration of hs-CRP was assessed by a least-
square regression analysis. FAS: fatty-acid synthase; hs-CRP: high-
sensitive C-reactive protein; ACS: acute coronary syndrome; PBMCs:
peripheral blood mononuclear cells.
Figure 1 Relative expression levels of FAS, IL-6 mRNA and
protein in PBMCs. PBMCs were isolated from peripheral blood of
ACS patients. Healthy subjects were treated as control group. a. FAS
and IL-6 mRNA were detected by realtime-PCR. All the effective data
were statistically analyzed by the 2-ΔΔCt method. b. FAS and IL-6
protein were detected by Western blotting. β-actin was the internal
control. *P<0.05 compared to the control group. FAS: fatty-acid
synthase; PBMCs: peripheral blood mononuclear cells; ACS: acute
coronary syndrome.
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ous study in Mesenchymal stem cells (MSCs) which
demonstrated that the decrease of FAS was dose
dependent in MSCs treated with EETs [40]. In their
study, they provided direct evidence that EETs induced
increased expression of heme oxygenase-1 (HO-1) led to
the increases in adiponectin, phosphorylation/inactiva-
tion of Acetyl-CoA carboxylase 1 (ACC1) and conse-
quently decreased levels of FAS [40]. Most important,
they concluded that increased expression of HO-1 might
be a trigger for changes in lipid metabolism. HO-1,
widely expressed in cells and tissues, is a rate-limiting
enzyme that catabolizes heme and is important for the
suppression of inflammatory responses [41]. Based on
these data, we speculated the possible mechanism of our
study was that sEHi lead to augmented circulation levels
of EETs, which increased expression of HO-1, triggered
a series reaction, consequently attenuated the levels ofFAS expression. But the detail of the mechanism is un-
known, and further studies are required.
Rae and Graham [14] showed that the C75, which was
found to be an inhibitor of FAS [42], effectively blocked
pro-atherogenic metabolic responses to a inflammatory
factor, preventing this factor from inducing increases in
macrophage triacylglycerol and cholesteryl ester content.
It has been suggested that lipid accumulation induced by
inflammation in cells could be reduced by inhibiting the
synthesis of fatty acid by FAS. Moreover, the last study
showed that induction of fatty acid synthesis by FAS was
absolutely necessary for monocyte differentiation and
the phagocytic activity of macrophages [9]. The inhib-
ition of FAS could prevent lipoprotein uptake during
monocyte differentiation [9], which was the crucial step
of the maturation of macrophages. Additionally, it has
been demonstrated previously that treatment with sEHi
reduced the area of atherosclerotic lesions, and these
effects were associated with a reduction of serum lipid
and IL-6 [43].
IL-6 plays a significant role in the development of acute
inflammatory responses, including endothelial and lympho-
cyte activation [44]. In our study, the increased expression
of IL-6 mRNA and protein in PBMCs from the ACS group
were inhibited by sEHi in a dose-dependent manner, which
was consistent with the anti-inflammatory properties of
sEHi in previous studies [22,43]. Resident macrophages
would not produce pro-inflammatory proteins, such as
TNF-α, IL-6, without nuclear factor kappa B (NF-κB)
Figure 4 Effects of sEHi on expression levels of FAS and IL-6
mRNA and protein in PBMCs. PBMCs were isolated from
peripheral blood of ACS patients. Then, t-AUCB, a kind of sEHi was
added to cells of ACS group in various concentrations (0, 10, 50,
100) μmol/L and incubated for 24 hours. a. FAS and IL-6 mRNA
were detected by real-time PCR. All the effective data were
statistically analyzed by 2-ΔΔCt. b. FAS and IL-6 protein were
detected by Western blots. β-actin was the internal control. *P<0.05
compared to the group without sEHi (t-AUCB 0 μmol/L). sEHi:
soluble epoxide hydrolase inhibitor; FAS: fatty-acid synthase; PBMCs:
peripheral blood mononuclear cells; ACS: acute coronary syndrome.
Figure 3 Linear relationships between expression levels of IL-6
mRNA and the serum concentration of hs-CRP in ACS. PBMCs
were isolated from peripheral blood of ACS patients. IL-6 mRNA was
detected by realtime-PCR. Hs-CRP was measured by immune
nephelometry. Relative expression levels of IL-6 mRNA means its
2-ΔΔCt value. Hs-CRP was log transformed to achieve normal
distribution. The linear relationship between expression levels of IL-6
mRNA and the serum concentration of hs-CRP was assessed by a
least-square regression analysis. FAS: fatty-acid synthase; hs-CRP:
high-sensitive C-reactive protein; ACS: acute coronary syndrome;
PBMCs: peripheral blood mononuclear cells.
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NF-κB was the underlying mechanism for elevated expres-
sion levels of IL-6 in PBMCs from patients with ACS.
Furthermore, it was not difficult to deduce that anti-
inflammatory properties of sEHi, especially lower expres-
sion levels of IL-6, might involve inhibition of NF-κB
activation, though NF-κB activation was not measured
directly in these studies. However, future studies need to
elucidate the underlying mechanisms.
Some limitations of our study should be considered.
Firstly, although SFA played an important role in the devel-
opment of ACS, we did not monitor the SFA in plaques or
plasma. In fact, we have realized the important role of
measurement of SFA in plaques, however there are some
difficulties: (1) as noted in our manuscript, we expected
the concentration of SFA in plaques was reduced by regu-
lating FAS, consequently decreased the occurrence of ACS.
But it was impossible to get the plaques of ACS patients.
(2) Afterwards, we figured out whether it was feasible to
detect the concentration of SFA in plasma instead of pla-
ques? But the answer is negative. Because the concentra-
tion of SFA in plasma was liable to be influenced by food
metabolism. Moreover, a study showed that the concentra-
tion of SFA in plaques was not associated with it in plasma
[7]. So it is not feasible to detect SFA in plasma instead
of plaques. Taken together, we could not detect the
concentration of SFA but speculated the reduction of
SFA in plaques theoretically. Secondly, ACS encompass
unstable angina, ST-elevation myocardial infarction(STEMI), and non-STEMI; however, we did not study
the expression of FAS among these different categories
of ACS. Thirdly, in our study, we studied the function
of FAS in vitro, but the results in vivo remained un-
known. Finally, the potential mechanisms underlying
the observed effects were undefined.
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In summary, the present study showed that inhibition of
sEH by t-AUCB reduced mRNA and protein expression
of FAS and inflammatoty factor, IL-6, in PBMCs from
the ACS group. These findings have led to the postulate
that sEHi might attenuate the development of ACS by
regulating lipid metabolism and inflammation as well as
preventing rupture of atherosclerotic lesions.
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